The Outsourcing Facilities Association is appealing a ruling that rejected their request for an injunction against the FDA’s ...

A Columbia University dermatologist argues that physicians in her specialty should be on the lookout for metabolic syndrome ...

Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.

Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize ...

US biopharma Viking Therapeutics developing therapies for metabolic and endocrine disorders, closed Tuesday’s trading 5% ...

Viking Therapeutics inks broad manufacturing pact with CordenPharma to support commercialization of VK2735: San Diego Wednesday, March 12, 2025, 17:00 Hrs [IST] Viking Therapeutic ...

Do you know what that is and why you would do it? A Ozempic is a drug that helps manage blood glucose levels in people living ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...